{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:02:40Z","timestamp":1784829760447,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03367-4","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:06:34Z","timestamp":1784826394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disagreement in rivaroxaban dosing between Cockcroft\u2013Gault and eGFR equations in nonvalvular atrial fibrillation: a statewide analysis"],"prefix":"10.1007","author":[{"given":"Amina","family":"Ammar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Edwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kaatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"DeCamillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Haymart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0540-785X","authenticated-orcid":false,"given":"Christopher","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"3367_CR1","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.15420\/aer.2025.33","volume":"14","author":"MF Karatela","year":"2025","unstructured":"Karatela MF, Calkins H (2025) The Global impact of atrial fibrillation. Arrhythmia Electrophysiol Rev 14:e28","journal-title":"Arrhythmia Electrophysiol Rev"},{"key":"3367_CR2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1124\/dmd.108.025569","volume":"375","author":"C Weinz","year":"2009","unstructured":"Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 375:1056\u20131064","journal-title":"Drug Metab Dispos"},{"key":"3367_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/jcph.1838","volume":"618","author":"V Ashton","year":"2021","unstructured":"Ashton V, Kerolus-Georgi S, Moore KT (2021) The pharmacology, efficacy, and safety of rivaroxaban in renally impaired patient populations. J Clin Pharmacol 618:1010\u20131026","journal-title":"J Clin Pharmacol"},{"key":"3367_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"36510","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 36510:883\u2013891","journal-title":"N Engl J Med"},{"key":"#cr-split#-3367_CR5.1","unstructured":"Rivaroxaban (Xarelto) prescribing information [Internet (ed) (2021) ]. Janssen Pharmaceuticals, Inc"},{"key":"#cr-split#-3367_CR5.2","unstructured":"[cited 2026 Mar 24]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215859s000lbl.pdf"},{"key":"3367_CR6","first-page":"31","volume":"161","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault H (1976) Prediction of creatinine clearance from serum creatinine. Nephron 161:31\u201341","journal-title":"Nephron"},{"key":"3367_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5858\/arpa.2012-0134-CP","volume":"1374","author":"AA Killeen","year":"2013","unstructured":"Killeen AA, Ashwood ER, Ventura CB, Styer P (2013) Recent trends in performance and current state of creatinine assays. Arch Pathol Lab Med 1374:496\u2013502","journal-title":"Arch Pathol Lab Med"},{"key":"3367_CR8","doi-asserted-by":"crossref","unstructured":"Brown DL, Masselink AJ, Lalla CD (2013) Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation. Ann Pharmacother 47(7\u20138):1039\u20131044","DOI":"10.1345\/aph.1S176"},{"key":"3367_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/j.1875-9114.2012.01098.x","volume":"327","author":"MA Winter","year":"2012","unstructured":"Winter MA, Guhr KN, Berg GM (2012) Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacother J Hum Pharmacol Drug Ther 327:604\u2013612","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"3367_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/j.ackd.2017.09.013","volume":"251","author":"WG Miller","year":"2018","unstructured":"Miller WG, Jones GR (2018) Estimated glomerular filtration rate; laboratory implementation and current global status. Adv Chronic Kidney Dis 251:7\u201313","journal-title":"Adv Chronic Kidney Dis"},{"key":"3367_CR11","first-page":"725","volume":"1942","author":"NA Khader","year":"2025","unstructured":"Khader NA, Kamath VG, Kamath SU, Rao IR, Prabhu AR (2025) Kidney function estimation equations: a narrative review. Ir J Med Sci 1971- 1942:725\u2013743","journal-title":"Ir J Med Sci 1971"},{"key":"3367_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/ajhp\/zxae317","volume":"8212","author":"WL St. Peter","year":"2025","unstructured":"St. Peter WL, Bzowyckyj AS, Anderson-Haag T, Awdishu L, Blackman M, Bland A et al (2025) Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: a consensus of the national kidney foundation workgroup for implementation of race-free eGFR-based medication-related decisions. Am J Health Syst Pharm 8212:644\u2013659","journal-title":"Am J Health Syst Pharm"},{"key":"3367_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jacasi.2021.11.006","volume":"21","author":"YH Chan","year":"2022","unstructured":"Chan YH, Chao TF, Lee HF, Yeh YH, Chang SH, Kuo CT et al (2022) Different renal function equations and dosing of direct oral anticoagulants in atrial fibrillation. JACC Asia 21:46\u201358","journal-title":"JACC Asia"},{"key":"3367_CR14","doi-asserted-by":"crossref","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159\u2013174","DOI":"10.2307\/2529310"},{"key":"3367_CR15","doi-asserted-by":"crossref","unstructured":"Yao RJR, Holmes DN, Andrade JG, Levin A, Piccini JP, Fordyce CB (2023) Variability in Nonvitamin K Oral anticoagulant dose eligibility and adjustment according to renal formulae and clinical outcomes in patients with atrial fibrillation with and without chronic kidney disease: insights from ORBIT-AF II. J Am Heart Assoc 12(6):e026605","DOI":"10.1161\/JAHA.122.026605"},{"key":"3367_CR16","doi-asserted-by":"crossref","unstructured":"Al-Maqbali JS, Al Alawi AM, Al-Adawi M, Al-Falahi Z, Al-Azizi A, Al Badi K et al (2022) Clinical associations with the differences in rivaroxaban dosing in patients with atrial fibrillation stratified by three renal function formulae. Pharm Pract 21(1):2758","DOI":"10.18549\/PharmPract.2023.1.2758"},{"key":"3367_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.metabol.2005.11.004","volume":"554","author":"J Verbraecken","year":"2006","unstructured":"Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L (2006) Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 554:515\u2013524","journal-title":"Metabolism"},{"key":"3367_CR18","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.ajkd.2020.04.010","volume":"763","author":"S Titan","year":"2020","unstructured":"Titan S, Miao S, Tighiouart H, Chen N, Shi H, Zhang L et al (2020) Performance of indexed and nonindexed estimated GFR. Am J Kidney Dis 763:446\u2013449","journal-title":"Am J Kidney Dis"},{"key":"3367_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jcla.21648","volume":"282","author":"B Redal-Baigorri","year":"2014","unstructured":"Redal-Baigorri B, Rasmussen K, Heaf JG (2014) Indexing glomerular filtration rate to body surface area: clinical consequences. J Clin Lab Anal 282:83\u201390","journal-title":"J Clin Lab Anal"},{"key":"3367_CR20","doi-asserted-by":"crossref","unstructured":"Mosteller R (1987) Simplified calculation of body-surface area. N Engl J Med 317(17):1098","DOI":"10.1056\/NEJM198710223171717"},{"key":"3367_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"531","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 531:1\u201316","journal-title":"Clin Pharmacokinet"},{"key":"3367_CR22","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s43440-020-00127-w","volume":"726","author":"MT D\u00e9ri","year":"2020","unstructured":"D\u00e9ri MT, Kiss \u00c1F, T\u00f3th K, Paulik J, S\u00e1rv\u00e1ry E, K\u00f3bori L et al (2020) End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s. Pharmacol Rep 726:1695\u20131705","journal-title":"Pharmacol Rep"},{"key":"3367_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.ackd.2015.10.002","volume":"232","author":"MA Ladda","year":"2016","unstructured":"Ladda MA, Goralski KB (2016) The effects of CKD on cytochrome P450\u2013mediated drug metabolism. Adv Chronic Kidney Dis 232:67\u201375","journal-title":"Adv Chronic Kidney Dis"},{"key":"3367_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/bcp.14127","volume":"863","author":"J Santos","year":"2020","unstructured":"Santos J, Ant\u00f3nio N, Rocha M, Fortuna A (2020) Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol 863:533\u2013547","journal-title":"Br J Clin Pharmacol"},{"key":"3367_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.amjmed.2019.01.025","volume":"1327","author":"R Arbel","year":"2019","unstructured":"Arbel R, Sergienko R, Hammerman A, Greenberg-Dotan S, Batat E, Avnery O et al (2019) Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med 1327:847\u2013855","journal-title":"Am J Med"},{"key":"3367_CR26","doi-asserted-by":"publisher","first-page":"100210","DOI":"10.1016\/j.tru.2025.100210","volume":"20","author":"M Jansson","year":"2025","unstructured":"Jansson M, Sj\u00e4lander S, Sj\u00f6gren V, Bj\u00f6rck F, Renlund H, Sj\u00e4lander A (2025) Clinical outcomes of direct oral anticoagulant off-label dosing in nonvalvular atrial fibrillation. Thromb Update 20:100210","journal-title":"Thromb Update"},{"key":"3367_CR27","doi-asserted-by":"crossref","unstructured":"Dawson T, DeCamillo D, Kong X, Shensky B, Kaatz S, Krol GD et al (2020) Correcting inappropriate prescribing of direct oral anticoagulants: a population health approach. J Am Heart Assoc 9(22):e016949","DOI":"10.1161\/JAHA.120.016949"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03367-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03367-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03367-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:06:36Z","timestamp":1784826396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03367-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":28,"alternative-id":["3367"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03367-4","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}